Daxor announces new findings from Duke University on BVA

Daxor (DXR) Corporation announces significant new findings from Duke University Medical Center published in the prestigious American Heart Journal. The research demonstrates how Blood Volume Analysis, BVA, enables precise measurement of red blood cell mass and effectively differentiates between true and dilutional anemia in heart failure patients. Dr. Veraprapas Kittipibul, the study’s lead investigator, outlined key findings: Anemia is prevalent in heart failure patients and can be categorized by type using BVA. Among heart failure patients diagnosed with anemia by WHO hemoglobin criteria, 60% had true anemia while 40% had dilutional pseudo-anemia. Patients with dilutional pseudo-anemia.showed a tendency toward higher heart failure hospitalization compared to those with no anemia or true anemia. No significant difference in heart failure hospitalization rates was observed across different RBCM profiles. Heart failure patients with RBCM deficit or true anemia demonstrated poorer exercise capacity.